Sat, Dec 27, 2014, 3:14 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

doron_allen 41 posts  |  Last Activity: 17 hours ago Member since: Mar 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    My target $1.15

    by boris.dark 19 hours ago
    doron_allen doron_allen 17 hours ago Flag

    Ceragon will show profits on Q1 2015 in a few weeks we may see $2.3 or more.

    Sentiment: Buy

  • Reply to

    Tec. chart above $3.6 direction $3.9

    by doron_allen Dec 10, 2014 12:59 PM
    doron_allen doron_allen Dec 10, 2014 1:12 PM Flag

    achen ken ;)

    Sentiment: Buy

  • good tec. signal for surge to $3.9 will be if we cross $3.6 level, parabolic sar. = 3.56 ; pivot = 3.55 and MA(50) =3.6. GL longs.

    Sentiment: Buy

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $58 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value $400 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value $0 million.

    Ampio Subsidiaries assets value.

    1. Vyrix $0 million.
    2. Luoxis $60 million.

    Total assets value: $530 million.

    Present Market cap. $169 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $10
    Present upside 313%

    Sentiment: Buy

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $58 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value $300 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value $0 million.

    Ampio Subsidiaries assets value.

    1. Vyrix $0 million.
    2. Luoxis $60 million.

    Total assets value: $430 million.

    Present Market cap. $175 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $8.3
    Present upside 245%

    Sentiment: Buy

  • Reply to

    Ampio Finances?

    by sluggobear Nov 13, 2014 2:25 AM
    doron_allen doron_allen Nov 13, 2014 2:40 AM Flag

    sluggobear The debt is Zero, cash on hand is $58 millio, estimate expenses on the next 12-16 months around $30 million. no convertible debt. They will not be able to find a partner before BLA. Hope I help.

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $58 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value *$300 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value *$150 million. Present Market Size $1.2 Billion. On 2018 Market Size $2.5 Billion.

    Ampio Subsidiaries assets value.

    1. Vyrix $0 million.
    2. Luoxis $60 million.

    Total assets value: $580 million.

    Present Market cap. $198 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $11.
    Present upside 292%

    * Modest and minimal estimate, some analysts estimate both drugs value around $1 billion.

    Sentiment: Strong Buy

  • Reply to

    Good news coming soon!

    by rock_adcock Oct 24, 2014 3:44 PM
    doron_allen doron_allen Oct 24, 2014 4:00 PM Flag

    The tec. is telling all the story....

    Sentiment: Strong Buy

  • doron_allen doron_allen Oct 24, 2014 2:23 PM Flag

    Nice posts, your posts are lifting AMPE higher, please continue!

    Sentiment: Strong Buy

  • Reply to

    Ampio Assets value vs Market Cap. Oct. 24, 2014.

    by doron_allen Oct 24, 2014 11:16 AM
    doron_allen doron_allen Oct 24, 2014 1:20 PM Flag

    Who told you that I can't name them? Aegis and Fordham

    Sentiment: Strong Buy

  • Reply to

    Ampio Assets value vs Market Cap. Oct. 24, 2014.

    by doron_allen Oct 24, 2014 11:16 AM
    doron_allen doron_allen Oct 24, 2014 12:58 PM Flag

    If you didn't realize Ampio is a dream investment, a small advice if you are not a dreamer invest in KO AA BA and ect.

    Sentiment: Strong Buy

  • Reply to

    Ampio Assets value vs Market Cap. Oct. 24, 2014.

    by doron_allen Oct 24, 2014 11:16 AM
    doron_allen doron_allen Oct 24, 2014 12:26 PM Flag

    The only reason that may bring me to stop posting at Ampio board will be balanced price and you can guess what is that price. B.T.W my target price is very modest, others on that board define it $25 or even $35.

    Sentiment: Strong Buy

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $60 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value *$300 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value *$150 million. Present Market Size $1.2 Billion. On 2018 Market Size $2.5 Billion.

    Ampio Subsidiaries assets value.

    1. Vyrix $150 million. IPO during the 2nd half of 2014.
    2. Luoxis $60 million.

    Total assets value: $730 million.

    Present Market cap. $202 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $14.
    Present upside 361%

    * Modest and minimal estimate, some analysts estimate both drugs value around $1 billion.

    Sentiment: Strong Buy

  • doron_allen doron_allen Oct 21, 2014 12:46 PM Flag

    About Vyrix the plan to go IPO is for the 2nd half of 2014 they didn't plan to do it before. "This week, AMPE announced that it had spun off its sexual dysfunctionbusiness into a new entity called Vyrix Pharmaceuticals. The assets will include Zertane and Zertane-ED (men's health). AMPE is expected to own between 50-80% of the new entity which is expected to have an IPO in 2H/14. The size of the AMPE investment is likely not going to be financially material, but in my view, the key is that this allows Ampio to have a greater focus on its core assets, those in osteoarthritis, and potentially have a cleaner monetization of the men's health assets which were not given lead burner access previously." Source Seeking Alpha Dec 20, 2013. Vyrix will raise around $30 million, company value around $150 million.

    Sentiment: Strong Buy

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $60 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value *$300 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value *$150 million. Present Market Size $1.2 Billion. On 2018 Market Size $2.5 Billion.

    Ampio Subsidiaries assets value.

    1. Vyrix $150 million. IPO during the 2nd half of 2014.
    2. Luoxis $60 million.

    Total assets value: $730 million.

    Preset Market cap. $207 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $14.
    Present upside 352%

    * Modest and minimal estimate, some analysts estimate both drugs value around $1 billion.

    Sentiment: Strong Buy

  • doron_allen doron_allen Oct 15, 2014 11:54 AM Flag

    IPO of $29 million say that company will get from investors cash $29 million (for 20% of shares) and Vyrix total value is $150 million (Ampion will hold the rest 80% of shares). About Optina™ revenue of $35 million reflect value of $350 - $450 million. Two leading analysts gave $14 target price after STEP failure, I am sure that they will upgrade target price back to $21 after positive PR for MI study. The bottom line: Today the share price is undervalued and we will see a recover correlated to events.

    Sentiment: Strong Buy

  • doron_allen doron_allen Oct 15, 2014 10:59 AM Flag

    The value in my calculations reflect the relative progress in the study.
    Ampion™ potential market size $2.5 Billion Ampio will have 3% from the market, expected revenue $75 million net income $30 million. The P/E (ttm): = 20-30 for companies from pharma field. We get a product value of $600 - $900 million.

    Sentiment: Strong Buy

  • The following calculation is an estimate, the data is from the media and company publications.

    Assets:

    1. Cash $60 million.
    2. Property Plant and Equipment $10 million.
    3. Ampion™ drug value *$300 million. Present Market Size $2.5 Billion.
    4. Optina™ drug value *$150 million. Present Market Size $1.2 Billion. On 2018 Market Size $2.5 Billion.

    Ampio Subsidiaries assets value.

    1. Vyrix $150 million. IPO doring the 2nd of 2014.
    2. Luoxis $60 million.

    Total assets value: $730 million.

    Preset Market cap. $182 million.

    Conclusions : There is a huge undervalue from the above calculation, fair value for share is $14.
    Present upside 400%

    * Modest and minimal estimate, some analysts estimate both drugs value around $1 billion.

    Sentiment: Strong Buy

  • Reply to

    Taking it down

    by jhof51 Oct 3, 2014 10:31 AM
    doron_allen doron_allen Oct 3, 2014 10:43 AM Flag

    Good question, after they take it down by $500 they are able to buy cheaper under $4 50,000 shares that are going to have a value of $5 after the next PR.....

    Sentiment: Strong Buy

  • Posted on Thursday, 02 October 2014 12:04
    US drug developer S1 Biopharma has filed documents with the Securities and Exchange Commission for an initial public offering (IPO) which could raise up to USD 40.25 million.
    The number of shares to be sold and the issue price have not been disclosed as yet.
    S1 Biopharma is planning to list the stock on Nasdaq under the symbol SXB.
    Some of the proceeds will be used for the development of the company’s product candidates, with the remainder earmarked for working capital and other general corporate purposes.
    MLV & Co. was named as the sole underwriter for the offering and has been granted a 30-day option to purchase additional shares. Law firm Duane Morris is advising the company on the transaction.
    New York City-based S1 Biopharma is a clinical-stage pharmaceuticals developer.
    The company focuses on the production of drugs for the treatment of male and female sexual dysfunction disorders. Its most advanced product candidate is Lorexys, which completed a phase 2a clinical trial earlier this year. Another of S1 Biopharma’s drugs, Orexa, is due to complete phase 2a in 2015.
    The company was incorporated as S1 Pharmaceuticals in October 2010, but was renamed in June 2012.
    For the first six months of 2014, S1 Biopharma reported operating expenses of USD 1.56 million, up 74.5 per cent on USD 891,842 for the same period in 2013. The company had total assets of USD 614,174, as of 30th June 2014.
    Vyrix Pharmaceuticals, another sexual dysfunction treatment developer, is also looking to carry out an IPO this year. Back in April, the Colorado-based firm announced it is planning to raise up to USD 28.75 million via the listing.

    Sentiment: Strong Buy

INSM
15.37+0.08(+0.52%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Tesla Motors, Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST